A 24-Week, Multi-Center, Open-Label Evaluation of Compliance and Tolerability of the Once-Daily 10 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease.
Phase of Trial: Phase IV
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Rivastigmine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms CARE
- Sponsors Novartis
- 28 Mar 2013 Actual end date changed from Sep 2011 to Oct 2011 as reported by ClinicalTrials.gov.
- 04 May 2012 Actual patient number is 380 as reported by ClinicalTrials.gov.
- 04 May 2012 Actual end date (1 Sep 2011) added as reported by ClinicalTrials.gov.